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BACKGROUND: Recent evidence has implicated the MAP kinase (MAPK) pathway with the development of castrate-resistant prostate
cancer (CRPC). We have previously reported gene amplification of critical members of this pathway with the development of
castrate-resistant disease. In addition, we have shown that rising Raf-1 expression, with the development of CRPC, influences time to
biochemical relapse. We therefore sought to further analyse the role of both Raf-1 and its downstream target MAPK in the molecular
pathogenesis of CRPC.
METHODS: Protein expression of Raf-1 and MAPK, including their activation status, was analysed using immunohistochemistry in a
database of 65 paired tumour specimens obtained before and after the development of CRPC and correlated with other members
of the pathway.
RESULTS: Patients whose nuclear expression of MAPK rose with the development of CRPC had a significantly shorter median time to
death following biochemical relapse (1.40 vs 3.00 years, P¼0.0255) as well as reduced disease-specific survival when compared with
those whose expression fell or remained unchanged (1.16 vs 2.62 years, P¼0.0005). Significant correlations were observed between
protein expression of Raf-1 and MAPK with the type 1 receptor tyrosine kinases, Her2 and epidermal growth factor receptor, as well
as the transcription factor AP-1 in CRPC tumours.
CONCLUSION: We conclude that the Her2/Raf-1/MAPK/AP-1 axis may promote the development of CRPC, leading to early relapse,
and reduced disease-specific survival. In addition, members of the pathway may act as novel therapeutic and/or diagnostic targets for
prostate cancer.
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Prostate cancer is one of the highest diagnosed forms of cancer in
the western world (CancerResearchUK, 2010) and is the second
most common cause of male cancer-related deaths (Debes and
Tindall, 2004). If diagnosed early, the disease tends to be localised
and organ specific, in these cases radical surgery and/or radio-
therapy can be highly successful. However, many patients present
with an advanced form, in these cases the primary form of
treatment in the UK is based on androgen-ablation therapy, which
was first established 50–60 years ago (Linja et al, 2001). This form
of treatment prevents the activation of androgen-regulated genes
by reducing the level of stimulation for the androgen receptor
(AR), established by Huggins and Hodges (2002) this form of
treatment has remained virtually unchanged for 60 years. This has
been shown to effectively reduce tumour growth in 70–80% of
men, and these are also known as hormone-naı ¨ve prostate cancer
(HNPC). However, it is commonly accepted that all patients will
eventually relapse with CRPC, for which there are very limited
treatment options. The development of CRPC ultimately leads to
disease progression, which is the main contributing factor for the
morbidity and mortality associated with prostate cancer (Dorkin
and Neal, 1997; Sciarra et al, 1999). Chemical control of androgens
is effective in localised disease; however, for high-grade, metastatic
disease, the best treatment option is surgical castration (Wirth
et al, 2004).
Early detection of prostate cancer is hindered by an inability to
distinguish between histological presence of cancerous changes
that may never progress to potentially fatal metastatic disease
(Culig et al, 2002). This indicates a great need to understand the
underlying mechanisms of prostate cancer to discover new forms
of detection and treatment. To address these issues, greater
understanding of the mechanisms involved and development of
new treatments is urgently required, as the incidence of prostate
cancer is expected to increase by 20% in the next 10–25 years
(Beemsterboer et al, 1999). Currently, levels of prostate-specific
antigen (PSA) are used to determine the presence of CRPC or
of progression from HNPC to CRPC (Stamey et al, 1987; Gao
et al, 1997).
The Raf family of serine/threonine kinases and the MAP kinase
(MAPK) pathway are heavily implicated in prostate cancer as
activation of the Raf/MAPK pathway increases prostate cancer cell
growth both AR-dependent and -independent under in vitro
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sconditions (Yeh et al, 1999; Bakin et al, 2003). Members of the Raf
family are activated by the Ras family of GTPases (Weinstein-
Oppenheimer et al, 2000), and translocate to the cell membrane
upon activation whereupon it activates MEK (MAPKK), initiating
a MAPK cascade (Weinstein-Oppenheimer et al, 2000). Mitogen-
activated protein kinase has been shown to induce Raf-1
activation, resulting in a positive feedback loop (Alessandrini
et al, 1997; Weinstein-Oppenheimer et al, 2000). Mitogen-activated
protein kinase has also been shown to increase the transcription of
androgen-dependent genes, independently of androgens by
phosphorylation of AR or its cofactors (Abreu-Martin et al,
1999; Ueda et al, 2002; Bakin et al, 2003; Franco et al, 2003).
Mutations and gene expression deregulation of both Ras and Raf
are associated with tumour growth and progression (Khleif et al,
1999; Weinstein-Oppenheimer et al, 2000). In addition, Raf and
MEK have both been shown to be overexpressed in non-metastatic
and metastatic prostate cancer cells (Weinstein-Oppenheimer et al,
2000; Fu et al, 2003). Mitogen-activated protein kinase activity has
been shown to be elevated in CRPC (Abreu-Martin et al, 1999;
Gioeli et al, 1999), in which activated MAPK is believed to be able
to stimulate prostate cancer cell growth independently of AR by
activating various transcription factors including AP-1 (a homo-
or heterodimer of phosphorylated c-jun and c-fos) and c-myc
(Weinstein-Oppenheimer et al, 2000). In fact, increased AP-1
expression has been linked to castrate resistance and decreased
patient survival (Edwards et al, 2004). In addition, it has been
shown that Raf-1 expression increases with the development of
CRPC and there is a significantly shorter time to relapse
(Mukherjee et al, 2005).
Although the Ras/Raf/MAPK pathway has been implicated in the
development of CRPC through cell-line and xenograft models
(Abreu-Martin et al, 1999; Bakin et al, 2003), its precise role in the
development of clinical CRPC is still poorly understood. The
further elucidation of its role would clearly have therapeutic
implications, as in vitro studies suggest inhibition of the pathway
in conjunction with hormone therapy or chemotherapy may
provide a novel method of treatment in CRPC (Bakin et al, 2003;
Zelivianski et al, 2003).
Here we evaluate and discuss the expression levels of Raf-1 and
MAPK (critical members of the MAPK cascade) and their
activation status in matched HNPC and CRPC tumours and
correlate expression levels with type 1 tyrosine kinase receptors, as
well as their downstream targets, AR and AP-1, in the same cohort
of patients.
PATIENTS AND METHODS
Patients
A total of 65 subjects who were recruited and met the specific
inclusion criteria of having developed CRPC, this was determined
by: firstly an initial response to androgen deprivation therapy,
defined as a fall in PSA levels of at least 50% following
orchidectomy or LHRH agonists and anti-androgen treatment.
Secondly, all subjects showed a subsequent relapse (defined as a
sustained rise in PSA levels despite maximal treatment). These
subjects were identified retrospectively and samples were retrieved
from archived stored specimens. Formalin-fixed tumour speci-
mens from initial diagnosis (before any therapy) and post-CRPC
development were obtained for this study, providing hormone-
naı ¨ve and castrate-resistant samples for each individual, respec-
tively. A total of 65 prostate cancer patients were included in this
study (130 tumours in total) (diagnosed between 1984 and 2000).
All tumours had patient identification removed, and the clinical
information database was anonymised. Ethical approval was
obtained from the Multicentre Research Ethics Committee for
Scotland (MREC/01/0/36) and Local Research and Ethical
Committees. Patients were only selected for analysis if they
initially responded to hormone treatment (in the form of
subcapsular bilateral orchidectomy or maximum androgen block-
ade), but subsequently relapsed (two consecutive rises in PSA
greater than 10%) and had a pre- and post-castrate-resistant tissue
sample available for analysis. Hormone-naı ¨ve tissue was obtained
from 18 patients by TRUS-guided biopsy and the remaining by
TURP, and castrate-resistant tumours were all obtained by TURP.
Information on AR, PSA (Edwards et al, 2003a), HER2, epidermal
growth factor receptor (EGFR) 6 (Edwards et al, 2006) and AP-1
(Edwards et al, 2004) expression levels and immunohistochemistry
in each of these samples had been identified previously.
Immunohistochemistry
Five micrometer paraffin-embedded tissue sections were used for
immunohistochemistry staining. Briefly, sections were de-paraffi-
nised with xylene and rehydrated. Sections were then incubated in
epitope retrieval solution (DakoCytomation, Glostrup, Denmark)
for 20min at 961C, and cooled down to room temperature. After
antigen retrieval, sections were blocked with horse serum (1.5%
horse serum/TBS) for 30min, followed by overnight incubation at
41C with appropriate primary antibodies. Overall Raf-1 expression
was assayed with mouse monoclonal antibodies (1:20 dilution;
Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA), whereas the
level of inactivated Raf-1 was analysed using rabbit polyclonal
antibodies (1:25 dilution; Cell Signaling Technology, Irvine, CA,
USA). Phosphorylated Raf-1 (pRaf-1) (Ser338) was detected with a
rat monoclonal antibody diluted 1:250 (Upstate Biotechnology,
Lake Placid, NY, USA). Total p42/p44 (MAPK) as well as activated
p42/p44 (phosphorylated at Thr202/204) was assessed using rabbit
polyclonal antibodies (1:25 and 1:50 dilutions, respectively; Cell
Signaling Technology). After primary antibody incubation, tissue
sections were washed with TBS and incubated with biotinylated
species-specific secondary antibodies (DakoCytomation). After
subsequent washes with TBS, streptavidin/HRP complexes and
DAB chromogene were used to visualise staining. Tissue sections
were then counterstained with haematoxylin.
Histoscoring
All immunostained tumour sections were quantified blindly and
independently by two observers, using a weighted histoscore
method at high magnification ( 400). Specific staining in each
tissue section was allocated 0 (no staining), 1 (weak intensity of
staining), 2 (moderate intensity) or 3 (strong intensity). The final
score (maximum 300) is calculated from the sum of:
ð1 %weakstainingÞþð 2 %moderatestainingÞ
þð 3 %strongstainingÞ
Statistical analysis
Statistical analysis was performed using the SPSS statistical
package (version 9.0). Protein expression data was not normally
distributed and is shown as median and inter-quartile ranges.
Wilcoxon signed rank tests were used to compare expression
between HNPC and CRPC tumours. Correlations (nonlinear)
between proteins were calculated using the Spearman rank test.
Time to relapse and survival analysis was conducted using
the Kaplan–Meier method and curves were compared with the
log-rank test.
Strong correlations are defined as having a Po0.01 and
r
2X0.25; moderate correlations are defined as having a Po0.05
and r
2o0.25, but X0.1; and weak correlations are defined with a
Po0.05 and r
2o0.1.
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Patient cohort characteristics
The clinical data collected and recorded for each patient included
age (median: 70 years; inter-quartile range: 66–74 years), PSA
level at diagnosis (median: 31ngml
 1; inter-quartile range:
7.8–109ngml
 1), PSA level at relapse (median: 10ngml
 1; inter-
quartile range: 4–11ngml
 1) and Gleason grade at diagnosis
(median: 8, inter-quartile range: 7–9). All patients underwent
biochemical relapse (median time to relapse: 2.54 years; inter-
quartile range: 1.51–4.62 years). All patients included in this study
were deceased (median time to death after relapse: 1.37 years;
inter-quartile range: 0.82–2.69). This resulted in an overall median
survival time of 4.5 years (inter-quartile range: 3.00–7.01). Patients
were diagnosed with locally advanced (46 patients) or metastatic
(19 patients) prostate cancer, and at the time of relapse the number
of patients presenting with metastatic disease had risen (40
patients). At diagnosis, patients either underwent surgery (27
orchidectomy) or androgen deprivation therapy (59 GnRH
analogue and/or anti-androgen deprivation therapy). Most
patients were deceased during the course of follow-up (46
patients), although some survived beyond follow-up (19 patients).
The presence of metastatic disease at diagnosis was associated
with reduced time to biochemical relapse (P¼0.037) and a trend
in overall patient survival (P¼0.06). High Gleason scores were
associated with more rapid biochemical relapse (P¼0.002), time
to death after biochemical relapse (P¼0.02) and disease-specific
survival (P¼0.001), confirming the association of these clinical
parameters with the progression of prostate cancer.
Expression and localisation of Raf-1 and MAPK
Raf-1 was observed in the cytoplasm and peri-membrane areas
(Figure 1A), and the inactive form of Raf-1 was found only in the
peri-membrane region (Figure 1B); however, the activated form of
Raf-1 was observed in the cytoplasm, nucleus and the cell
membrane (Figure 1C). Mitogen-activated protein kinase and
phosphorylated MAPK (pMAPK) (Thr202/204) were observed in
the nucleus and cytoplasm (Figure 1D).
Overall, comparison of HNPC tumours and CRPC tumours
revealed no differences in total or average expression levels of
either Raf-1 (and all phosphorylated forms) (Table 1) or MAPK
(activated or inactivate, nuclear or cytoplasmic) (Table 2).
However, analysis of matched pairs revealed a subgroup that
showed significant increases in Raf-1 and MAPK levels in CRPC
tumours.
We have previously reported that patients whose Raf-1
expression rose in this cohort with the development of CRPC
had a significantly shorter time to relapse than those patients who
had a fall or no change (P¼0.0005) (Mukherjee et al, 2005).
Consistent with this observation, patients with rising levels of
nuclear pRaf (Ser338, activated Raf-1) had a significantly shorter
time to biochemical relapse (2.2 years; range: 1.84–2.56 years) by
2.4 years when compared with patients who showed a fall in levels
(4.6 years; range: 3.4–5.8 years) (P¼0.01) (Figure 2).
Patients whose nuclear MAPK expression rose with the
development of CRPC had a significantly shorter time to death
from relapse (1.40 (1.20–1.61) years) compared with samples that
showed a fall or no change in expression (3.00 (1.43–4.57) years),
P¼0.0255 (Figure 3A). This translated into a shorter disease-
specific survival of 3.37 (1.58–5.16 ) years compared with 6.89
(5.70–8.08) years, P¼0.0068 (Figure 3B). Interestingly, there was
also an association seen between rising cytoplasmic pMAPK
(Thr202/204) expression and reduced time to biochemical relapse
(P¼0.06).
Relative protein expression levels in hormone-naı ¨ve
prostate cancer
In HNPC tumours, Raf-1 correlated with the inactive form, pRaf
(Ser259), before relapse (P¼0.0041, r
2¼0.1201). Nuclear pRaf
(Ser338) and cytoplasmic pRaf (Ser338) strongly correlated with
each other (P¼0.0035, r
2¼0.1381). No correlations between total
Raf-1 and cytoplasmic pRaf (Ser338) or nuclear pRaf (Ser338)
expression were evident. In addition no correlations were observed
between the inactive form of pRaf (Ser259) and nuclear pRaf
(Ser338) or cytoplasmic pRaf (Ser338).
Total cytoplasmic expression of MAPK correlated with total
nuclear expression of MAPK (P¼0.0126, r
2¼0.1009), activated
Raf Phospho raf 259 Phospho raf 338
Phospho MAPK MAPK
Figure 1 Raf and MAPK localisation in prostate cancer. Tissue sections counterstained with haematoxylin showing (magnification  400) (A) total Raf;
(B) inactive pRaf (Ser259); (C) active pRaf (Ser338); (D) total MAPK; and (E) activated (phospho) MAPK localisations in prostate cancer. Inset shows higher
magnification images.
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2¼0.1044) and the cytoplasmic
expression of MAPK (Thr202/204) (Po0.0001, r
2¼0.3391). Total
nuclear MAPK expression correlated very strongly with the
activated form of MAPK (Thr202/204) in the nucleus (Po0.0001,
r
2¼0.3447) and pMAPK (Thr202/204) in the cytoplasm
(P¼0.0075, r
2¼0.1250). Activated cytoplasmic MAPK (Thr202/
204) also very strongly associated with its activated expression
(MAPK pThr202) in the nucleus (Po0.0001, r
2¼0.5210).
In addition, Raf-1 and pRaf (Ser259) both correlated with the
cytoplasmic expression of MAPK (Po0.0001, r
2¼0.2979 and
P¼0.0005, r
2¼0.1879, respectively) and activated cytoplasmic
MAPK (Thr202/204) (P¼0.0007, r
2¼0.1826 and P¼0.0069,
r
2¼0.1214, respectively). Raf-1 also correlated with nuclear
activated MAPK (Thr202/204) (P¼0.0022, r
2¼0.1525). There
were no correlations seen between pRaf (Ser338) and MAPK or
pMAPK (Thr202/204).
Relative protein expression levels in CRPC
In CRPC tumours, Raf-1 correlated with pRaf (Ser259) strongly
(P¼0.0003, r
2¼0.1778). The nuclear and cytoplasmic forms of
pRaf (Ser338) also strongly correlated with each other (Po0.0001,
r
2¼0.6009). Similarly to HNPC, protein expression of the inactive
form of pRaf (Ser259) and the active forms of pRaf (Ser338) did
not correlate in the cell cytoplasm or nucleus.
After the development of CRPC, cytoplasmic expression of total
MAPK became strongly associated with the expression of total
MAPK in the nucleus (P¼o0.0001, r
2¼0.2564) and more weakly
with its activated form, pMAPK (Thr202/204), in the nucleus
(P¼0.0194, r
2¼0.0864). Cytoplasmic expression of total MAPK
continued to show a correlation with its activated form in the
cytoplasm (MAPK pThr202/204) (P¼0.0004, r
2¼0.1861). Acti-
vated cytoplasmic MAPK (Thr202/204) remained strongly asso-
ciated with activated nuclear MAPK (Thr202/204) (Po0.0001,
r
2¼0.5350).
Raf-1 showed similar associations with cytoplasmic and nuclear
MAPK expression (Po0.0001, r
2¼0.2141 and P¼0.0016,
r
2¼0.1426, respectively). Cytoplasmic MAPK also correlated
with pRaf (Ser259) (P¼0.0026, r
2¼0.1329). Similarly to HNPC
tumours, no correlations were noted between pRaf (Ser338) and
MAPK in any location or form.
Relative expression levels of Raf-1 and MAPK compared
with upstream and downstream targets in hormone-naı ¨ve
prostate cancer
Analysis of the upstream activators EGFR and Her2, as well as the
downstream targets AR and AP-1, has previously been carried out
on the same cohort of patients (Edwards et al, 2003a, 2004; Bartlett
et al, 2005). We therefore correlated Raf-1 and MAPK expression
with these previous results, to determine the differences in the
entire pathway in the transition from HNPC to CRPC.
In hormone-naı ¨ve tumours, expression of the putative growth
factor receptor Her2 correlated with Raf-1 expression (P¼0.0099,
r
2¼0.1333) and the nuclear and cytoplasmic expression of
pMAPK (Thr202/204) (P¼0.0150, r
2¼0.1300 and P¼0.0017,
r
2¼0.2074, respectively). Once activated, the phosphorylated form
of Her2 (pHer2) showed moderate correlations with Raf-1
(P¼0.0056, r
2¼0.1435), pRaf (Ser259) (P¼0.0052, r
2¼0.1459)
and cytoplasmic MAPK expression (P¼0.0123, r
2¼0.1211)
(Figure 4), but not the activated forms of Raf or MAPK.
No correlations were seen with EGFR in HNPC tumours, except
weak correlations with Raf-1 (P¼0.0439, r
2¼0.06008) and
pMAPK (Thr202/204) (nuclear) (P¼0.0243, r
2¼0.0844). However,
the mutant variant, EGFR vIII, did correlate strongly with
cytoplasmic expression of MAPK (Po0.0001, r
2¼0.2617) and to
a weaker extent with Raf-1 (P¼0.025, r
2¼0.07965) and pRaf
(Ser259) (P¼0.0323, r
2¼0.07295).
Table 1 Protein histoscores for phosphorylated Raf in HNPC and CRPC tumours
HNPC CRPC P-value % Fall % Unchanged % Rise
pRaf (Ser259) 127.5 (105–160) 137.5 (89–175) 0.42 14 (9/65) 69 (45/65) 17 (11/65)
pRaf (Ser338) nuclear 55 (0–125) 50 (0–200) 0.22 16 (8/50) 54 (27/50) 30 (15/50)
pRaf (Ser338) cytoplasmic 100 (20–114) 92.5 (23–103) 0.43 32 (16/50) 40 (20/50) 28 (14/50)
Abbreviations: CRPC¼castrate-resistant prostate cancer; HNPC¼hormone-naı ¨ve prostate cancer.
Table 2 MAPK protein histoscores in HNPC and CRPC tumours
HNPC CRPC P-value % Fall % Unchanged % Rise
MAPK (nuclear) 60 (20–100) 80 (30–100) 0.27 27 (15/56) 39 (22/56) 34 (19/56)
MAPK (cytoplasm) 150 (120–190) 160 (130–190) 0.52 18 (10/56) 59 (33/56) 23 (13/56)
pMAPK (nuclear) 90 (32–144) 90 (52–119) 0.82 23 (13/56) 50 (28/56) 27 (15/56)
pMAPK (cytoplasm) 120 (76–160) 120 (92–150) 0.93 20 (11/56) 60 (34/56) 20 (11/56)
Abbreviations: CRPC¼castrate-resistant prostate cancer; HNPC¼hormone-naı ¨ve prostate cancer; MAPK¼mitogen-activated protein kinase.
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Figure 2 Kaplan–Meier plot for patients who showed a significant fall in
pRaf (ser338) expression with the development of CRPC compared with
those who did not. There was a significant difference in time to relapse in
these patients (P¼0.01).
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sFurther downstream, activated pRaf (Ser338) in the cytoplasm
strongly correlated with phosphorylated c-jun (P¼0.0009,
r
2¼0.2673) and total MAPK (cytoplasmic) correlated weakly with
c-Fos (P¼0.0453, r
2¼0.09418) (Figure 5). There were no
correlations seen between MAPK and its activated form with
c-jun, phospho c-Jun or c-Fos. In addition, PSA showed weak
correlations with Raf-1 (P¼0.0142, r
2¼0.09604), pRaf (Ser259)
(P¼0.043, r
2¼0.06547), and showed links to overall MAPK levels,
MAPK (nuclear) (P¼0.0029, r
2¼0.1502) and MAPK (cytoplasmic)
(Po0.0001, r
2¼0.2467), with strong ties to the activated forms,
pMAPK (Thr202/204) (cytoplasmic) (Po0.0001, r
2¼0.2891) and
pMAPK (Thr202/204) (nuclear) (P¼0.0001, r
2¼0.2233) (Figure 6),
whereas AR showed no correlations with Raf, MAPK or any of
their forms.
Relative expression levels of Raf-1 and MAPK compared
with upstream and downstream targets in CRPC
After the development of CRPC, Her2 no longer showed a
correlation with Raf-1 nor a negative association became evident
between pRaf (Ser338) both in the cytoplasm (P¼0.0035,
r
2¼0.1854) and nucleus (P¼0.0068, r
2¼0.1581) with Her2. In
addition, the activated form (pHer2) correlated with pRaf (Ser259)
(P¼0.0008, r
2¼0.2011). Interestingly, the activated cytoplasmic
form of Raf showed a positive weak correlation with the pHer2
(P¼0.0363, r
2¼0.09376) (Figure 7). Furthermore, no correlations
were evident between Her2 or pHer2 with MAPK in any form. All
associations between EGFR and EGFR vIII disappeared after
progression to CRPC.
A moderate positive correlation was seen between pRaf (Ser259)
and AR (P¼0.0035, r
2¼0.1154), whereas a negative correlation is
evident between nuclear MAPK and AR (P¼0.0429, r
2¼0.06066).
There was no correlation (positive or negative) shown between
total Raf-1 expression and AR. In addition, there were no
correlations noted between either Raf-1 (any form) or MAPK
(any form) and PSA level. More correlations were noted with
components of the downstream transcription factor AP-1.
Correlations were evident between phosphorylated c-jun and
cytoplasmic pRaf (Ser338) (P¼0.0026, r
2¼0.2192) and pRaf
(Ser259) (P¼0.0278, r
2¼0.1077). There was also a correlation
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Figure 4 Raf-1 and MAPK show correlations with Her2 and activated Her2 (pHer2) in HNPC tumours. (A) Her2 correlation with Raf-1 (P¼0.0099,
r
2¼0.1333); (B) Her2 correlation with pMAPK nuclear (P¼0.015, r
2¼0.13); (C) Her2 correlation with pMAPK cytoplasmic (P¼0.0017, r
2¼0.2074); (D)
pHer2 correlation with Raf-1 (P¼0.0056, r
2¼0.1435); (E) pHer2 correlation with pRaf (Ser259) (P¼0.0052, r
2¼0.1459); and (F) pHer2 correlation with
MAPK cytoplasmic (P¼0.0123, r
2¼0.1211).
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Figure 3 Kaplan–Meier plot for patients who showed a rise in nuclear MAPK expression with the development of CRPC compared with those who did
not. There was a significant difference in (A) time to death from relapse in these patient subgroups (P¼0.0255) and (B) disease-specific survival in these
patient subgroups (P¼0.0068).
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Figure 5 Cytoplasmic pRaf (Ser338) and cytoplasmic MAPK correlate with phospho c-Jun and c-Fos, respectively, in HNPC. (A) Phospho c-Jun
correlation with pRaf (Ser338) cytoplasmic (P¼0.0009, r
2¼0.2673) and (B) c-Fos correlation with MAPK cytoplasmic (P¼0.0453, r
2¼0.0942).
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Figure 6 Prostate-specific antigen correlates with Raf and MAPK in HNPC tumours. (A) PSA correlation with Raf-1 (P¼0.0142, r
2¼0.096); (B) PSA
correlation with pRaf (Ser259) (P¼0.043, r
2¼0.0655); (C) PSA correlation with MAPK nuclear (P¼0.0029, r
2¼0.1502); (D) PSA correlation with MAPK
cytoplasmic (Po0.0001, r
2¼0.2467); (E) PSA correlation with pMAPK cytoplasmic (Po0.0001, r
2¼0.2891); and (F) PSA correlation with pMAPK nuclear
(P¼0.0001, r
2¼0.2233).
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Figure 7 Activated Raf correlates with Her2 and activated Her2 (pHer2) in CRPC tumours. (A) Her2 correlation with pRaf (Ser338) cytoplasmic
(P¼0.0035, r
2¼0.1854); (B) Her2 correlation with pRaf (Ser338) nuclear (P¼0.0068, r
2¼0.1581); (C) pHer2 correlation with pRaf (Ser259) (P¼0.0008,
r
2¼0.2011); and (D) pHer2 correlation with pRaf (Ser338) cytoplasmic (P¼0.0363, r
2¼0.0938).
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2¼0.1512), and
between the nuclear and cytoplasmic expression of pMAPK
(Thr202/204) and c-jun (P¼0.0146, r
2¼0.1368 and P¼0.0178,
r
2¼0.1295, respectively) (Figure 8).
DISCUSSION
The MAPK pathway is known to have critical roles in the control of
the cell cycle, growth and prevention of apoptosis (Bradham and
McClay, 2006). This pathway has been implicated in the
development of CRPC and circumvention of AR involvement in
prostate cancer (Edwards et al, 2003b). Raf is well known to be
involved in a broad range of cancers (Jilaveanu et al, 2009) and is
considered to be an oncogene that drives the MAPK pathway and
proliferation to enhance tumourigenesis (Karreth et al, 2009). The
upstream activator of Raf, Ras, has also previously been identified
as being linked to tumourigenesis (Edwards and Bartlett, 2005).
The distribution of Raf-1 (Roskoski, 2010) and MAPK
(Cuadrado and Nebreda, 2010) observed by immunohisto-
chemistry is consistent with the current understanding of their
cellular localisation and functions, indicating that their localisation
and functions were not disrupted during tumourigenesis, their
levels however showed a very broad range of fluctuations. The
data presented here suggests that Raf-1 activates MAPK in the
cytoplasm, which in turn translocates to the nucleus. No correla-
tions were observed between activated Raf-1 and activated MAPK;
however, this was not unexpected as Raf-1 becomes rapidly
inactivated and phosphorylated at serine 259 in the cytoplasm.
Raf has been shown to have the ability to circumvent the MAPK
pathway by acting directly upon retinoblastoma protein (Dhillon
et al, 2003; Dasgupta et al, 2004). The very strong correlations
between cytoplasmic and nuclear activated Raf levels and the
weaker correlations between Raf and MAPK may indicate that a
small portion of Raf activity may be attributable to MAPK-
independent action. The lack of any clear links between active Raf
and active MAPK in CRPC would appear to indicate that the two
pathways can and do operate independently in the latter stages of
prostate cancer. In addition, the tight correlations present between
the various forms of MAPK after transition to CRPC is a strong
indicator that this pathway has become very active in either the
transition to or progression of CRPC.
There are several correlations between PSA levels and both Raf
and MAPK (all forms) indicating a clear and distinct link between
PSA and these pathways in HNPC. Interestingly, these correlations
are completely absent in CRPC, giving further indication that these
pathways have become dislocated with the general indicators
associated with prostate cancer (i.e., PSA and Gleason score). This
may indicate a reason for PSA being useful in the initial diagnosis
of prostate cancer, but not in determining hormone relapse or
overall survival (Supplementary Figure 1). Furthermore, this may
indicate that markers in the Raf and MAPK pathways may be more
appropriate targets for monitoring disease progression.
Interestingly, there are links between active MAPK (Thr202/204)
and HER2 in HNPC, which are completely absent in CRPC; in
addition, there are no links between pRaf (Ser338) and Her2 or
pHer2 in HNPC, which shifts to negative correlations between pRaf
(Ser338) and Her2 in CRPC. Intriguingly, there is a complete swing
from activated cytoplasmic Raf (Ser338) from this negative
correlation with Her2 to a positive correlation with pHer2. This
may be an indicator that the Her2 signalling pathway has become
active and is signalling through Raf; this idea is enhanced by the
correlation of cytoplasmic activated Raf (Ser338) with phospho
c-Jun. Taken together, these data suggest that Her2 is signalling
through Raf and ultimately through c-Jun (AP-1), as we have
suggested previously (Edwards et al, 2004), to circumvent AR
activity after the tumour has become insensitive to androgens, as
AP-1 has been shown to act independently of AR to activate some
of the AR-associated genes (Sato et al, 1997). Furthermore, the
links between activated MAPK and c-Jun, but a lack of any links
with Her2 or EGFR, is further evidence that MAPK and Raf are
acting independently of each other to achieve the same end goal.
Both MAPK and PKC have been shown to phosphorylate c-Jun
directly to stabilise it (Sato et al, 1997; Sadar et al, 1999; Bonaccorsi
et al, 2003); however, the lack of correlation between MAPK and
phospho c-Jun, in addition to our previous findings that phopho
c-Jun is upregulated in 61% of cases (Edwards et al, 2004), suggests
that MAPK is not acting through this mechanism. In fact, the
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Figure 8 Raf and activated MAPK correlate with components of AP-1 in CRPC. (A) Phospho c-Jun correlation with pRaf (Ser338) cytoplasmic
(P¼0.0026, r
2¼0.2192); (B) phospho c-Jun correlation with pRaf (Ser259) (P¼0.0278, r
2¼0.1077); (C) c-Fos correlation with Raf-1 (P¼0.0131,
r
2¼0.1512); (D) c-Jun correlation with pMAPK nuclear (P¼0.0146, r
2¼0.1368); and (E) c-Jun correlation with pMAPK cytoplasmic (P¼0.0178,
r
2¼0.1295).
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sevidence indicates that MAPK may have a role in c-Jun activation of
AR, by promotion of dimerisation (Wise et al, 1998), in the absence
of hormones. This provides a mechanism for the activation of
androgen-activated genes without the need for the androgen signal,
thus making the tumour insensitive to hormone withdrawal. The
links between Raf and the components of AP-1 are stronger than with
MAPK, which may further suggest that Raf is the important
component in driving the stabilisation of AP-1. This evidence
suggests that two pathways to circumvent the need for hormones may
be present and active in CRPC, and these allow tumours to continue
to grow unabated without the need for hormones to drive
proliferation and metastasis. Furthermore, it indicates that members
of the Raf and MAPK pathways would be potential targets for
intervention therapy in the treatment of CRPC tumours.
In addition, we have previously reported an increase in AR
levels in 65% of CRPC cases (Edwards et al, 2001), which alone was
not overly significant; however, combined with stabilisation
through c-Jun and phosphorylation from the MAPK cascade, the
small increase becomes highly significant with increased activity.
This may also explain the correlation that exists between levels of
MAPK in the nucleus and levels of AR found in CRPC tumours.
From the results presented here, it is evident that increasing
levels of Raf-1 and/or MAPK are indicative of more rapid
biochemical relapse and a more rapid decline into CRPC, which
ultimately results in reduced survival times, with tumours showing
more severe and aggressive action. This suggests that these
members of this pathway are vital components and may be used
as indicators of disease severity, providing a more accurate system
for grading prostate cancer, in particular CRPC, than other
systems in use, for example ,breast cancer (Galea et al, 1992),
which have proven insufficient in classifying prostate cancer.
Furthermore, it suggests that these pathways are involved in the
development of CRPC. Ultimately, the Raf and MAPK pathways
may turn out to be excellent targets for preventative therapy, as
well as providing potential prognostic and/or diagnostic markers.
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